

Data Sharing Statement

Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. DOI: 10.1056/NEJMoa1814427.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	fervenza.fernando@mayo.edu
When will data availability begin?	18 months after publication
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	Analytic/Statistical code. Informed Consent Form
Additional information about supporting documents	—
How or where can supporting documents be obtained?	fervenza.fernando@mayo.edu
When will supporting documents availability begin?	With publication
When will supporting documents availability end?	—
To whom will data be available?	Researchers whose proposed use of the data has been approved).
For what type of analysis or purpose?	Secondary analyses
By what mechanism?	Researchers need to write an proposal that will be evaluated by the study PIs.
Any other restrictions?	—
Additional information	—

This statement was posted on July 4, 2019, at NEJM.org.